

# Weekly Gemcitabine for the Treatment of Biliary Tract

Investigational New Drugs

22, 193-198

DOI: 10.1023/b:drug.0000011797.09549.53

Citation Report

#	ARTICLE	IF	CITATIONS
1	Phase II study of S-1 in patients with advanced biliary tract cancer. British Journal of Cancer, 2004, 91, 1769-1774.	6.4	143
2	Palliative management of hilar cholangiocarcinoma. Surgical Oncology, 2005, 14, 59-74.	1.6	61
3	Regional and Systemic Chemotherapy for Primary Hepatobiliary Cancers and for Colorectal Cancer Metastatic to the Liver. Seminars in Radiation Oncology, 2005, 15, 284-298.	2.2	18
4	Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer, 2005, 5, 61.	2.6	27
5	Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer, 2005, 104, 1237-1245.	4.1	33
6	The Role of Gemcitabine in the Treatment of Cholangiocarcinoma and Gallbladder Cancer: A Systematic Review. Canadian Journal of Gastroenterology & Hepatology, 2005, 19, 711-716.	1.7	52
7	Single-agent Gemcitabine in the Treatment of Advanced Biliary Tract Cancers: a Phase II Study. Japanese Journal of Clinical Oncology, 2005, 35, 68-73.	1.3	64
8	Phase II Trial of High-Dose Conformal Radiation Therapy With Concurrent Hepatic Artery Floxuridine for Unresectable Intrahepatic Malignancies. Journal of Clinical Oncology, 2005, 23, 8739-8747.	1.6	308
9	Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. Journal of Cancer Research and Clinical Oncology, 2006, 132, 745-755.	2.5	52
10	Chemoradiotherapy in gallbladder cancer. Journal of Surgical Oncology, 2006, 93, 699-704.	1.7	43
11	Single-Agent Gemcitabine for Biliary Tract Cancers. Oncology, 2006, 70, 358-365.	1.9	23
12	Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. Annals of Oncology, 2006, 17, v153-v157.	1.2	21
13	Cholangiocarcinoma and its management. Gut, 2007, 56, 1755-1756.	12.1	38
14	A Multi-center Retrospective Analysis of Survival Benefits of Chemotherapy for Unresectable Biliary Tract Cancer. Japanese Journal of Clinical Oncology, 2007, 37, 843-851.	1.3	94
15	Treatment Options for Hepatobiliary and Pancreatic Cancer. Mayo Clinic Proceedings, 2007, 82, 628-637.	3.0	58
16	Antimetabolites. , 2007, , 55-79.		4
17	Gemcitabine in advanced biliary tract cancers. Critical Reviews in Oncology/Hematology, 2007, 61, 230-242.	4.4	17
18	Antitumor Effect of Gemcitabine on Orthotopically Inoculated Human Gallbladder Cancer Cells in Nude Mice. Annals of Surgical Oncology, 2007, 14, 1374-1380.	1.5	13

#	ARTICLE	IF	CITATIONS
19	A Phase II Study of Gemcitabine and Capecitabine in Advanced Cholangiocarcinoma and Carcinoma of the Gallbladder: A Single-Institution Prospective Study. <i>Annals of Surgical Oncology</i> , 2007, 14, 3202-3209.	1.5	68
20	Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 321-328.	2.3	51
21	Establishment of a novel orthotopic xenograft model of human gallbladder carcinoma. <i>Clinical and Experimental Metastasis</i> , 2007, 24, 141-148.	3.3	15
22	Pemetrexed and Gemcitabine for Biliary Tract and Gallbladder Carcinomas: a North Central Cancer Treatment Group (NCCTG) Phase I and II Trial, N9943. <i>Journal of Gastrointestinal Cancer</i> , 2007, 38, 87-94.	1.3	9
23	Phase-II Study of Gemcitabine and Cisplatin in Patients with Metastatic Biliary and Gallbladder Cancer. <i>Digestive Diseases and Sciences</i> , 2008, 53, 564-570.	2.3	56
24	Is There a Role for Cholecystectomy in Gallbladder Carcinoma Discovered to be Unresectable for Cure at Laparotomy?. <i>World Journal of Surgery</i> , 2008, 32, 2683-2687.	1.6	7
25	Guidelines for chemotherapy of biliary tract and ampullary carcinomas. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2008, 15, 55-62.	2.0	59
26	Postoperative adjuvant treatments for biliary tract cancer. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2008, 15, 463-467.	2.0	8
27	Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. <i>BMC Cancer</i> , 2008, 8, 374.	2.6	51
28	Gallbladder cancer – A comprehensive review. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2008, 6, 101-110.	1.8	147
29	EGFR Expression in Gallbladder Carcinoma in North America. <i>International Journal of Medical Sciences</i> , 2008, 5, 285-291.	2.5	31
30	Non-surgical treatment. , 0, , 195-213.		0
31	A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 65, 113-120.	2.3	21
32	Second-Line Treatment With a Combination of Continuous 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Conti-Fam) in Gemcitabine-Pretreated Pancreatic and Biliary Tract Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 348-352.	1.3	54
33	Adjuvant Gemcitabine Plus S-1 Chemotherapy Improves Survival After Aggressive Surgical Resection for Advanced Biliary Carcinoma. <i>Annals of Surgery</i> , 2009, 250, 950-956.	4.2	107
35	A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2010, 118, 139-144.	1.4	40
36	Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. <i>Hpb</i> , 2010, 12, 418-426.	0.3	23
37	Experience of Gemcitabine plus Oxaliplatin Chemotherapy in Patients with Advanced Biliary Tract Carcinoma. <i>Chemotherapy</i> , 2010, 56, 234-238.	1.6	15

#	ARTICLE	IF	CITATIONS
38	Treatment Efficacy/Safety and Prognostic Factors in Patients with Advanced Biliary Tract Cancer Receiving Gemcitabine Monotherapy: An Analysis of 100 Cases. <i>Oncology</i> , 2010, 79, 39-45.	1.9	23
39	Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 31-39.	4.4	33
40	A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1429-1434.	2.3	56
41	Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 379-388.	2.3	24
42	Targeted Therapy for Biliary Tract Cancer. <i>Cancers</i> , 2011, 3, 2243-2254.	3.7	14
43	Efficacy and Safety of Gemcitabine Monotherapy for Patients with Advanced Biliary Tract Cancer. <i>Journal of Nippon Medical School</i> , 2012, 79, 204-212.	0.9	2
44	Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2012, 19, 301-305.	2.6	10
45	Biliary tract carcinomas: From chemotherapy to targeted therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 136-148.	4.4	39
46	Biliary tract tumors: past, present and future. <i>Chinese-German Journal of Clinical Oncology</i> , 2013, 12, 86-92.	0.1	1
47	Role of Aquaporin-5 in Gallbladder Carcinoma. <i>European Surgical Research</i> , 2013, 51, 108-117.	1.3	19
48	Phase II Trial of Combination Chemotherapy with Gemcitabine, 5-Fluorouracil and Cisplatin for Advanced Cancers of the Bile Duct, Gallbladder, and Ampulla of Vater. <i>Tumori</i> , 2013, 99, 139-144.	1.1	12
49	Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives. <i>ISRN Hepatology</i> , 2014, 2014, 1-13.	0.9	34
50	Second-line chemotherapy in advanced biliary cancer: a systematic review. <i>Annals of Oncology</i> , 2014, 25, 2328-2338.	1.2	279
51	Surgical Management of Intra-Hepatic Cholangiocarcinoma. <i>Medical Radiology</i> , 2014, , 241-252.	0.1	1
52	Proximal Biliary Tumors. <i>Surgical Clinics of North America</i> , 2014, 94, 311-323.	1.5	6
53	Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer. <i>Cancer</i> , 2014, 120, 278-285.	4.1	187
54	Hilar Cholangiocarcinoma: expert consensus statement. <i>Hpb</i> , 2015, 17, 691-699.	0.3	298
55	Gallbladder Cancer in the 21st Century. <i>Journal of Oncology</i> , 2015, 2015, 1-26.	1.3	195

#	ARTICLE	IF	CITATIONS
56	Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. <i>European Journal of Cancer</i> , 2015, 51, 1694-1703.	2.8	25
57	Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. <i>Hepatic Oncology</i> , 2015, 2, 39-50.	4.2	10
58	Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo. <i>Anti-Cancer Drugs</i> , 2016, 27, 600-608.	1.4	7
59	Point-of-Care Clinical Guide: Cholangiocarcinoma. , 2016, , 287-320.		0
60	New Horizons for Precision Medicine in Biliary Tract Cancers. <i>Cancer Discovery</i> , 2017, 7, 943-962.	9.4	419
61	Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma. <i>Current Oncology Reports</i> , 2017, 19, 50.	4.0	17
62	Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2020, 112, 200-210.	6.3	90
63	Current and New Biomarkers for Early Detection, Prognostic Stratification, and Management of Gallbladder Cancer Patients. <i>Cancers</i> , 2020, 12, 3670.	3.7	12
64	Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 170-185.	3.7	226
65	Therapy for advanced cholangiocarcinoma: Current knowledge and future potential. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 618-628.	3.6	18
66	Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 759-772.	4.1	8
67	Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103328.	4.4	25
68	A clinicoepidemiological and management profile of metastatic carcinoma gallbladder in the northeast part of Indian patients in a tertiary care center. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 428.	0.9	1
69	Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101). <i>PLoS ONE</i> , 2015, 10, e0143072.	2.5	16
70	Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study. <i>Oncotarget</i> , 2017, 8, 17246-17257.	1.8	26
71	Therapy for hilar cholangiocarcinoma. <i>Siberian Journal of Oncology</i> , 2019, 18, 103-115.	0.3	6
72	Clinical and Translational Research Challenges in Biliary Tract Cancers. <i>Current Medicinal Chemistry</i> , 2020, 27, 4756-4777.	2.4	21
73	Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. <i>World Journal of Gastroenterology</i> , 2008, 14, 5210.	3.3	110

#	ARTICLE	IF	CITATIONS
74	A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensitivity test-guided systemic chemotherapy. World Journal of Gastroenterology, 2009, 15, 5228.	3.3	5
75	Adjuvant surgery for advanced extrahepatic cholangiocarcinoma. World Journal of Gastroenterology, 2013, 19, 6934.	3.3	12
76	Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World Journal of Hepatology, 2010, 2, 58.	2.0	53
77	A Case of Common Bile Duct Cancer That Completely Responded to Combination Chemotherapy of Gemcitabine and TS-1. Gut and Liver, 2013, 7, 371-376.	2.9	7
78	Biliary Cancer. UNIPA Springer Series, 2021, , 675-688.	0.1	0
79	Malignant Tumors. , 2010, , 1519-1566.		0
80	Gemcitabine Alone or in Combination with Cisplatin for Advanced Biliary Tract Carcinomas: an Overview of Clinical Evidence. Asian Pacific Journal of Cancer Prevention, 2013, 14, 877-883.	1.2	5
81	Current Treatment for Gallbladder Cancer. , 2015, , 189-215.		1
82	Is combination chemotherapy of cisplatin and gemcitabine in the first-line treatment of advanced gallbladder cancer the right choice? A study in indian patients from the gangetic belt. Clinical Cancer Investigation Journal, 2020, 9, 63.	0.9	1
83	Cancer of the Liver and Bile Ducts. , 2006, , 752-770.		0
86	Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater. Tumori, 2013, 99, 139-44.	1.1	8
87	Identification of Novel Ribonucleotide Reductase Inhibitors for Therapeutic Application in Bile Tract Cancer: An Advanced Pharmacoinformatics Study. Biomolecules, 2022, 12, 1279.	4.0	1
88	Update on immunotherapy in the management of gallbladder cancer. Immunotherapy, 0, , .	2.0	0
89	Biliary Tract. Hot Topics in Acute Care Surgery and Trauma, 2023, , 189-224.	0.1	0